Select Medical Balances Growth, Margin Strain in Earnings Call

Select Medical ((SEM)) has held its Q1 earnings call. Read on for the main highlights of the call.

Select Medical’s latest earnings call painted a balanced picture for investors, with solid top-line growth and standout inpatient rehabilitation results offset by weaker profits and rising leverage. Management struck a cautiously confident tone, emphasizing operational progress and development growth while acknowledging reimbursement pressures, margin compression, and the added debt tied to its pending take‑private deal.

Take-Private Deal Sets New Course for Shareholders

Select Medical’s Board unanimously approved an agreement to be acquired for $16.50 per share, with closing targeted for mid‑2026 subject to remaining approvals. The company will go private at that point, funded in part by a new $1.0 billion senior secured term loan priced at SOFR plus 3%, which will materially increase leverage and interest expense.

Steady Consolidated Revenue Growth Across Divisions

Total revenue rose 5% year over year, with all three operating divisions contributing to the gain and demonstrating resilient demand for post‑acute and outpatient services. While the top line expanded, profitability did not keep pace, underscoring the impact of reimbursement challenges, mix shifts, and operational pressures in several key businesses.

Inpatient Rehabilitation Leads with Double-Digit Growth

Inpatient rehabilitation was the clear outperformer, with revenue climbing more than 14% to roughly $351.9 million and adjusted EBITDA up 15% to $81.1 million. Patient metrics were strong, including a 3% increase in revenue per patient day, 12% growth in average daily census, and occupancy rising to 83% overall and 87% on a same‑store basis, nudging margins higher to 23%.

Development Pipeline Adds Beds and Future Capacity

The company expanded its footprint year‑to‑date by adding 166 beds across three newly opened inpatient rehab hospitals. Looking ahead to 2026–2027, management plans to bring on another 275 beds, split between 209 rehab and 66 critical illness beds, including new AtlantiCare and Jersey City hospitals and additional acute rehab, neuro units, and Banner‑branded capacity.

Outpatient Volumes Grow but Pricing Stalls

Outpatient revenue increased more than 4% to $321.3 million, driven by a similar rise in patient visits that points to solid underlying demand. However, net revenue per visit was flat at $102, suggesting limited pricing power and highlighting the need for cost discipline and mix management to translate volume growth into stronger earnings.

Favorable CMS Proposals Offer Modest Tailwind

Management highlighted proposed FY2027 CMS rules that would raise the standard federal payment rate for inpatient rehab by about 2.6% and for long‑term acute care hospitals by roughly 2.66%. With the high‑cost outlier threshold expected to remain unchanged, these proposed adjustments would provide modest reimbursement tailwinds if finalized, particularly for the inpatient portfolio.

Guidance and Capital Return Plans Held Steady

The company reaffirmed its 2026 outlook, calling for revenue between $5.6 billion and $5.8 billion and adjusted EBITDA of $520 million to $540 million, alongside fully diluted EPS of $1.22 to $1.32. Capital spending is projected at $200 million to $220 million, and the Board approved a quarterly cash dividend of $0.0625 per share, signaling confidence despite near‑term earnings pressure.

Interest Costs Contained and Liquidity Cushion Intact

Interest expense in the quarter edged down to $28.3 million from $29.1 million a year earlier, reflecting relatively stable funding costs before the new term loan. Liquidity remained solid with $443.5 million of revolver availability and net leverage of 3.75x under its credit agreements, giving the company some flexibility to fund growth and navigate volatility.

EBITDA and EPS Slide Despite Revenue Gains

Consolidated adjusted EBITDA fell 6.5% year over year to $141.0 million from $151.4 million, underscoring the margin pressures running through parts of the portfolio. Earnings per share declined to $0.35 from $0.44, or $0.36 on an adjusted basis after take‑private costs, signaling that cost and payer dynamics are eroding a portion of the company’s revenue growth.

Critical Illness Hospitals Hit by MA Conversion Issues

The critical illness recovery hospitals reported essentially flat revenue at $638.8 million versus $637.0 million but saw adjusted EBITDA drop 15% to $73.4 million and margins compress to 11.5% from 13.6%. Management attributed roughly $13 million to $14 million of the decline to lower Medicare Advantage conversion and higher denials, pressuring both volumes and profitability.

Outpatient Margins Squeezed as Clinics Are Rationalized

Outpatient adjusted EBITDA slipped to $22.0 million from $24.3 million a year earlier, with margin falling to 6.8% from 7.9%, indicating that earnings are lagging volume growth. The quarter included about $1 million of costs tied to exiting four Oregon clinics, and management signaled more targeted exits or consolidations could follow in underperforming markets.

Leverage Already High with More Debt Coming

Select Medical ended the quarter with $1.9 billion of total debt and only $25.7 million of cash, translating to net leverage of 3.75x on its credit metrics. The planned $1.0 billion term loan needed for the take‑private transaction will push leverage meaningfully higher and increase interest‑rate exposure, raising the stakes for execution and cash‑flow generation.

Medicare Advantage Denials Create Broad-Based Pressure

Beyond the critical illness line, management cited reduced Medicare Advantage conversion and rising denial rates across hospital‑based segments, including long‑term acute care and rehab facilities. These payer dynamics weighed on quarterly volumes and margins and add another layer of uncertainty as the company works through appeal processes and adjusts its contracting and documentation.

Cash Flow Trails Investment as CapEx Stays Elevated

Operating cash flow for the quarter totaled $37.9 million, while investing activities consumed $56.7 million, including $58.9 million in property and equipment spending. The gap shows that Select Medical is investing ahead of current cash generation to support its development pipeline, putting a premium on future ramp‑up and maintaining access to external capital.

Segment Margin Swings Underscore Forecast Challenges

Management emphasized that the critical illness segment remains difficult to forecast quarter to quarter given seasonality and payer behavior, leading to earnings volatility. The outpatient segment also requires further operational improvements and market rationalizations to restore margins, leaving some uncertainty around how quickly consolidated profitability can recover.

Guidance and Regulatory Tailwinds Shape the Outlook

Looking ahead, Select Medical’s reiterated 2026 guidance suggests management expects revenue growth and efficiency measures to offset current headwinds and support higher EBITDA and EPS. Potential CMS rate increases for inpatient rehab and long‑term acute care, combined with a robust bed expansion plan and ample revolver capacity, form the backbone of its forward‑looking narrative despite higher leverage and payer risk.

Select Medical’s call ultimately balanced optimism about growth and regulatory trends with realism about margin pressure, Medicare Advantage challenges, and a heavier debt load post‑transaction. For investors, the story hinges on whether strong inpatient rehabilitation performance and a growing development pipeline can translate into sustained cash flow and deleveraging once the company is private and the current operational headwinds begin to ease.